ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

11 links0 made here, not in the record16 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT02154490Lung-MAP:Biomarker-TargetedSecond-Line Therapy inTreating Patients WithRecurrent Stage IV SquamousCell Lung CancerSWOG Cancer Research NetworkcompletedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedDRUGSDocetaxelIntervention entry›Nov 18 · Rule based · ExposureExposureDurvalumabIntervention entry›Nov 3 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposureErlotinibEntry “Erlotinib Hydrochloride”, read…›Nov 18 · Rule based · ExposureExposureAZD4547Entry “FGFR Inhibitor AZD4547”, read …›Nov 18 · Rule based · ExposureExposureIpilimumabIntervention entry›Nov 2 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposureNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposurePalbociclibIntervention entry›Nov 3 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposureRilotumumabIntervention entry›Nov 18 · Rule based · ExposureExposureTalazoparibIntervention entry›Nov 18 · Rule based · ExposureExposureTaselisibIntervention entry›Nov 18 · Rule based · ExposureExposureTremelimumabIntervention entry›Nov 3 · Claude Opus 5.5 · ExposureNov 18 · Rule based · ExposureExposure

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Durvalumab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Durvalumab”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Exposure
Exposure · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2NivolumabClaude Opus 5.5ExposureCurrent
Nov 2IpilimumabClaude Opus 5.5ExposureCurrent
Nov 3DurvalumabClaude Opus 5.5ExposureCurrent
Nov 3TremelimumabClaude Opus 5.5ExposureCurrent
Nov 3PalbociclibClaude Opus 5.5ExposureCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 18DocetaxelRule based · role ruleExposureCurrent
Nov 18DurvalumabRule based · role ruleExposureAgrees
Nov 18ErlotinibRule based · role ruleExposureCurrent
Nov 18AZD4547Rule based · role ruleExposureCurrent
Nov 18IpilimumabRule based · role ruleExposureAgrees
Nov 18NivolumabRule based · role ruleExposureAgrees
Nov 18PalbociclibRule based · role ruleExposureAgrees
Nov 18RilotumumabRule based · role ruleExposureCurrent
Nov 18TalazoparibRule based · role ruleExposureCurrent
Nov 18TaselisibRule based · role ruleExposureCurrent
Nov 18TremelimumabRule based · role ruleExposureAgrees

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.